28 June - 1 July 2017
Barcelona, Spain

Scientific Agenda

Skip to Day 2: Thursday, 29 June 2017

Skip to Day 3: Friday, 30 June 2017

Skip to Day 4: Saturday, 1 July 2017

 

Wednesday, 28 June 2017

12:30

Expert discussion: Neo-adjuvant/adjuvant treatment in gastric cancer
(by invitation only)
Scientific Committee and Selected Experts

13:30

Concurrent lunch mini-symposium begins

14:30

Concurrent lunch mini-symposium adjourns

Session I: Opening, Selected Abstracts, and Opening Lectures

Chairs: Eric Van Cutsem, MD, PhD, Mario Dicato, MD and Josep Tabernero, MD, PhD

14:45

Welcome and Introduction: Congress Chairs
Eric Van Cutsem, MD, PhD, Mario Dicato, MD and Josep Tabernero, MD, PhD

14:50

Presentation of selected abstracts

Survival analysis of patients with solid pseudopapillary tumors of the pancreas in a multicenter retrospective cohort
Brandon Huffman, et al., O-002

15:20

Opening Lecture 1: Cancer evolution in circulating tumor DNA
Alberto Bardelli, PhD

15:50

Opening Lecture 2: The role of the microbiome in cancer medicine
James Goedert, MD

Session II: Cancer of the Pancreas and Bile Ducts

Chairs: Jordan Berlin, MD and Thomas Seufferlein, MD

16:20

Screening in familial and hereditary pancreatic cancer
Margaret A. Tempero, MD

16:40

Diagnostic modalities for defining resectability (CT, EUS, MRI)
Miriam Klauß, MD

17:00

Is adjuvant or neo-adjuvant treatment for pancreatic cancer the way to go?
Volker Heinemann, MD

17:20

Presentation of selected abstracts

PEGPH20 Improves PFS in Patients with Metastatic Pancreatic Ductal Adenocarcinoma: A Randomized Phase 2 Study in Combination With nab-Paclitaxel/Gemcitabine +)
Andrew Hendifar, et al., O-003

Tumor Hyaluronan May Predict Benefit from PEGPH20 When Added to nab Paclitaxel/Gemcitabine in Patients with Previously Untreated Metastatic Pancreatic Ductal Adenocarcinoma (mPDA)
Andrew Hendifar, et al., O-028

Immunologic and Objective Tumor Responses to PEGylated Human IL-10 (AM0010) with 5- FU/LV and Oxaliplatin (FOLFOX) in Metastatic Pancreatic Adenocarcinoma (PDAC)
J. Randolph Hecht, et al., O-003

18:00

Improving the outcome of patients with metastatic pancreatic cancer
Thomas Seufferlein, MD

18:20

New agents/strategies on the horizon in pancreatic cancer
Philip A. Philip, MD, PhD, FRCP

18:40

Adjourn

19:00

Concurrent evening non-profit symposia begin
ESDO Research Workshop in Digestive Oncology: Nutrition in GI Cancer
Innovations in Care in the Next 12 Months: 14th ESO Colorectal Cancer Observatory

20:30

Concurrent evening non-profit symposia adjourn

20:30

Welcome reception


Thursday, 29 June 2017

Session III: Meet the Expert Concurrent Presentations

Parallel with Session IV: Interpreting Clinical Trials Results

08:00

Anal cancer
Michel Ducreux, MD, PhD and Karin Haustermans, MD, PhD

Cholangiocarcinoma and gall bladder cancer
Jordan D. Berlin, MD and Thomas Gruenberger, MD

Implementation of a wait and see program for rectal cancer: Pitfalls
Andre D'Hoore, MD, PhD and Rodrigo Perez, MD

Session IV: Interpreting Clinical Trials Results

Parallel with Session III: Meet the Expert Concurrent Presentations and Session V: Esophageal and Gastric Cancers
Chairs: Mario Dicato and Margaret A. Tempero, MD

08:00

Statistical interpretation and validity of clinical trials
Lindsay A. Renfro, PhD

08:20

Clinical interpretation and validity of clinical trials: When do they become practice changing?
Alberto Sobrero, MD

08:40

How relevant are the ESMO and ASCO clinical benefit scales: Do they impact our practice?
Fortunato Ciardiello, MD, PhD and and Deborah Schrag, MD, MPH

09:10

Biosimilars: How much evidence do we need?
Mario Dicato, MD

09:40

Roundtable discussion

09:45

Session adjourns

Session V: Esophageal and Gastric Cancers

Parallel with Session IV: Interpreting Clinical Trials Results
Chairs: Andrés Cervantes, MD, PhD, Jaroslaw Regula, MD

09:00

Presentation of selected abstract

Signet ring cell carcinoma of early gastric cancer, is endoscopic treatment really risky?
Hee Seok Moon, et al., O-005

09:10

Minimally invasive surgery for cancer of the esophagus
Christophe Mariette, MD, PhD

09:30

New evolutions for the neo-adjuvant and adjuvant treatment of esophageal cancer
Florian Lordick, MD, PhD

09:50

Surgery versus chemotherapy in esophageal cancer

10:05

Gastric carcinogenesis of gastric cancer through the eyes of a pathologist
Fatima Carneiro, MD, PhD

10:25

Keynote Lecture 1: Progress in unraveling the molecular taxonomy in gastric cancer
Patrick Tan, MD, PhD

10:55

Break and poster viewing
Posters to be presented: Clinical/basic non-CRC abstracts
Poster discussion guided tours

Session VI: Gastric Cancer

Chairs: David Cunningham, MD and Eric Van Cutsem, MD, PhD

11:25

Presentation of selected abstracts

Randomized, controlled phase III trial comparing 3D and 2D laparoscopic gastrectomy for gastric cancer
Changming Huang, et al., O-006

11:45

Neo-adjuvant/Adjuvant treatment in gastric cancer: What is optimal approach in 2017? Case based discussions
Ian Chau, MD

12:05

Presentation of selected abstracts

Nivolumab Monotherapy in Patients with Advanced Gastric of Gastroesophageal Junction (GEJ) Cancer and 2 or More Prior Treatment Regimens: Sub-Analysis of the CheckMate 032 Study
Patrick Ott, et al., O-007

12:25

Metastatic gastric cancer: What are the indications and what is the impact of targeting the HER2 pathway?
Andrés Cervantes, MD, PhD

12:35

Metastatic gastric cancer: What are the indications and what is the impact of angiogenesis inhibitors?
Yelena Janjigian, MD

12:45

Metastatic gastric cancer: What are the indications and what is the impact of check-point inhibitors?
Kohei Shitara, MD

12:55

Metastatic gastric cancer: What are the indications and what is the impact of stem-cell inhibition
Julien Taieb, MD

13:05

Discussion: How to prioritize between angiogenesis inhibitors and check-point inhibitors

13:10

Session adjourns

13:30

Concurrent luncheon symposia begin

15:00

Concurrent luncheon symposia adjourn

Session VII: Diseases and Cancers of the Liver

Chairs: Rachel Riechelmann, MD, PhD and Chris Verslype, MD, PhD

15:10

Presentation of selected abstract

Efficacy, tolerability and impact on quality of life of selective internal radiation therapy (with yttrium 90 resin microspheres) or sorafenib in patients with locally advanced hepatocellular carcinoma: the SARAH trial
Mohamed Bouattour et al., LBA-001

15:30

Controversy debate: Hepatocellular carcinoma: Case scenarios

Medical treatment first
Jordi Bruix, MD

Locoregional treatment first
Michel Ducreux, MD, PhD

16:00

New targets and new agents in HCC
Bruno Sangro, MD

 

16:20

Break and poster viewing
Posters to be presented: Clinical/Basic non-CRC abstracts

Session VIII: Inflammation, Genetics, NETs and HCC

Chairs: Rachel Riechelmann, MD, PhD and Chris Verslype, MD, PhD

16:50

IBD related GI cancers: Are they different? 
Franck Carbonnel, MD

17:10

How to do MSI testing?
Pierre Laurent-Puig, MD, PhD

17:30

When and how do go BRCA testing in GI cancer and what are the implications? 
Judith Balmaña, MD, PhD

17:50

Pathological classification of NET
Aurel Perren, MD

18:10

Controversy debate: Targeted agents versus PRRT in NET: Case scenarios

Targeted agents first
Ramon Salazar, MD

PRRT first
Jonathan Strosberg, MD

18:40

Presentation of selected abstracts

Efficacy and Safety of Nivolumab in Patients with Advanced Hepatocellular Carcinoma Analyzed by Patient Age: a Sub-Analysis of the CheckMate 040 Study
Ignacio Melero, et al., O-008

Updated overall survival (OS) analysis from the international, phase 3, randomized, placebo-controlled RESORCE trial of regorafenib for patients with hepatocellular carcinoma (HCC) who progressed on sorafenib treatment
Jordi Bruix, et al., O-009

19:00

Adjourn


Friday, 30 June 2017

Session IX: Meet the Expert Concurrent Presentations

Parallel with Session X: Presentation of Selected Abstracts: Colorectal Cancer, Session XI: Presentation of Selected Abstracts: Miscellaneous, and Session XII: ESMO Session: Focus on Young Medical Oncologists

08:00

Carcinoma of unknown origin
George Pentheroudakis, MD

Recent advances in management of GIST
John Zalcberg, MD

Workshop: Liver directed therapies: Radioembolisation, chemoembolization and surgery for metastatic CRC: Case-based session
Bernard Nordlinger, MD and Julien Taieb, MD, PhD

Thrombosis and cancer
Mario Dicato, MD

Session X: Presentation of Selected Abstracts- Colorectal Cancer

Parallel with Session IX: Meet the Expert Concurrent Presentations, Session XI: Presentation of Selected Abstracts: New Drugs in GI Cancer and Abstracts on Non-Colorectal Cancer
Chairs: Heinz-Josef Lenz, MD and Brigette B. Ma, MD

08:00

Presentation of selected abstracts

Impact in prognosis of circulating tumor DNA mutant allele fraction (MAF) in RAS mutant metastatic colorectal cancer (mCRC)
Enrique Sanz-García, et al., O-010

RET rearrangements define a new and rare molecular subtype of metastatic colorectal cancer (mCRC)
Filippo Pietrantonio, et al., O-011

Impact of prior bevacizumab treatment of VEGFA and PIGF levels and patient outcomes: A retrospective analysis of baseline plasma samples from the VELOUR trial
Eric Van Cutsem, et al., O-012

Discussant: Brigette B. Ma, MD

08:40

Presentation of selected abstracts

Systematic liquid biopsy identifies novel and heterogeneous mechanisms of acquired resistance in gastrointestinal (GI) cancer patients
Aparna Parikh, et al., O-001

The prognostic impact of primary tumor location in patients undergoing resection for colorectal liver metastasis: A propensity score-matched analysis
Yuichi Goto, et al., O-013

Prognostic and predictive role of neutrophils/lymphocytes ratio in metastatic colorectal cancer: A retrospective analysis of the TRIBE study by GONO
Emanuela Dell' Aquila, et al., O-014

Prognostic value of primary tumor location in stage III colon cancer is associated with RAS and BRAF mutational status
Julien Taieb, et al., O-015

FOLFOX/Bevacizumab +/- Irinotecan in advanced colorectal cancer (AIO) “CHARTA”: Final results and multivariate prognostic factor analysis
Hans-Joachim Schmoll et al., LBA-007

Discussant: Heinz-Josef Lenz, MD

09:45

Session adjourns

Session XI: Presentation of Selected Abstracts: New Drugs in GI Cancer and Abstracts on Non-Colorectal Cancer

Parallel with Session IX: Meet the Expert Concurrent Presentations, Session X: Presentation of Selected Abstracts: Colorectal Cancer
Chair: Jordan D. Berlin, MD

08:00

Presentation of selected abstracts

Molecular variations between small bowel adenocarcinomas (SBAs), right-sided colon cancers (RT-Colon), and gastroesophageal cancers (GEC)
Mohamed Salem, et al., O-018

A phase Ib/II study of cancer stemness inhibitor napabucasin in combination with gemcitabine (gem) & nab-paclitaxel (nabPTX) in metastatic pancreatic adenocarcinoma (mPDAC) patients (pts)
Tanios Bekaii-Saab, et al., LBA-002

Phase 1b/II study of cancer stemness inhibitor napabucasin in combination with FOLFIRI +/- Bevacizumab (bev) in metastatic colorectal cancer (mCRC) Patients (pts)
BH O’Neil, et al., LBA-003

Novel carcinoembryonic antigen T-cell bispecific (CEA-TCB) antibody: Preliminary clinical data as a single agent and in combination with atezolizumab in patients with metastatic colorectal cancer (mCRC)
G. Argilés, et al., LBA-004

Discussant: Rachel Riechelmann, MD

08:50

Presentation of selected abstracts

Ramucirumab plus pembrolizumab in previously treated advanced or metastatic biliary tract cancer: A multi-disease phase 1 study
Hendrik-Tobias Arkenau, et al., O-019

Early clinical efficacy of TAS-120, a covalently bound FGFR inhibitor, in patients with cholangiocarcinoma
Lipika Goyal, et al., O-020

Frequency and impact of tumor genotyping in clinical practice of patients with advanced biliary tract cancers (ABTCs)
Stephanie Reyes, et al., O-021

Relative contribution of baseline variables in a nomogram to predict survival in patients treated with nab-paclitaxel plus gemcitabine or gemcitabine alone for metastatic pancreatic cancer
David Goldstein, et al., O-017

Discussant: Jordan D. Berlin, MD

09:45

Session adjourns

Session XII: ESMO Session: Focus on Young Medical Oncologists

Parallel with Session IX: Meet the Expert Concurrent Presentations, Session X: Presentation of Selected Abstracts: Colorectal Cancer, and Session XI: Presentation of Selected Abstracts: Non-Colorectal

Part 1: Scientific Session

08:00

Liquid biopsies in managing CRC: Are we ready for prime time?
Andrea Sartore Bianchi, MD

08:20

Next frontiers in BRAF therapeutics
Elena Elez, MD, PhD

Part 2: Career Development

08:40

How to develop a career path in the current panorama of GI oncology in Europe
Fotios Loupakis, MD

09:00

The importance of mentorship in the European environment
Dirk Arnold, MD, PhD

09:20

Session adjourns

Session XIII: From Epidemiology to Prevention of GI Cancer

Chairs: Nadir Arber, MD, MHA, and Jaroslaw Regula, MD

09:10

Presentation of selected abstracts

Validation of Nu.Q™ colorectal cancer screening triage test to identify FIT positive individuals at low risk of screen relevant neoplasia
Mark Eccleston, et al., O-022

Mediterranean diet components are negatively associated with advanced colorectal polyps in a population-based case-control study
Naomi Fliss Isakov, et al., O-023

Should a single nucleotide variant in TGFBR1 modify colorectal cancer screening recommendations?
Garry Mahon, et al.,O-024

09:40

Recommendations for surveillance of adenomas
Jaroslaw Regula, MD

10:00

Can we improve screening methods of colorectal cancer?
Nadir Arber, MD, MHA

10:20

Are we understanding better the adenoma - carcinoma transition?
Eduardo Vilar Sanchez, MD, PhD

10:40

Travel grant award ceremony

10:45

Break and poster viewing
Posters to be presented: Clinical/Basic CRC abstracts
Poster discussion guided tours

Session XIV: Multimodality Therapy for Rectal Cancer

Chairs: Karin Haustermans, MD and PhD, Ali Shamseddine, MD, FRCP

11:15

Organ preservation in rectal cancer: How and for whom?
Rodrigo Perez, MD

11:35

Advances and challenges in the surgical treatment of locally advanced rectal cancer
Andre D'Hoore, MD, PhD

11:55

Defining the strategy in oligometastatic rectal cancer

The oncologists point of view
Dirk Arnold, MD, PhD

The surgeon's point of view
Bernard Nordlinger, MD

The radiation oncologist point of view
Felipe A. Calvo, MD

12:45

Case discussion on rectal cancer

13:00

Session Adjourns

13:20

Concurrent luncheon symposia begin

14:50

Concurrent luncheon symposia adjourn

Session XV: Immune Mechanisms and Immune Therapy in GI Cancer

Chairs: Scott Kopetz, MD, PhD and Josep Tabernero, MD, PhD

15:00

Keynote Lecture 2: Understanding the relevant immune mechanisms in GI cancer
Pierre Coulie, MD, PhD

15:30

The immune and stromal classification of colorectal cancer
Wolf H. Fridman, MD, PhD

15:50

Molecular classification of colon cancer: New insights
Sabine Tejpar, MD, PhD

16:10

Does the molecular and immunologic classifications have clinical implications in 2017?
Rodrigo Dienstmann, MD

16:30

Presentation of selected abstract

VELOUR trial biomarkers update: Impact of RAS, BRAF, and sidedness on aflibercept activity
Sabine Tejpar, et al., LBA-005

16:40

Break and poster viewing
Abstracts to be presented: Clinical/Basic CRC abstracts

Session XVI: Molecular Biology in CRC

Chairs: Fortunato Ciardiello, MD and PhD, Rodrigo Dienstmann, MD

17:10

How to approach the patient with a BRAF mutant tumor?
Jan Schellens, MD

17:30

Acquired resistance to EGFR antibodies: How to manage?
Federica Di Nicolantonio, MD

17:50

Immune therapy in CRC
Josep Tabernero, MD, PhD

18:10

Immune therapy in non-CRC GI cancer
Yelena Janjigian, MD

18:30

Current status and perspectives on liquid biopsies in mCRC
Scott Kopetz, MD, PhD

Session XVII: Highlights of ASCO and ESMO GI Abstracts

Chairs: Fortunato Ciardiello, MD and PhD, Rodrigo Dienstmann, MD

18:50

Selected abstracts: Highlights of poster discussions and posters at ESMO GI

Non-colorectal
Chris Verslype, MD, PhD

Colorectal
Ali Shamseddine, MD, FRCP

19:10

Adjourn


Saturday, 1 July 2017

Session XVIII: Colorectal Cancer: Tumor Board

Chairs: Mario Dicato, MD and , Eric Van Cutsem, MD, PhD

08:30

Multidisciplinary tumor board on resectable and borderline/potentially resectable liver metastases
David Cunningham, MD; Brigette B. Ma, MD; and Bernard Nordlinger, MD

09:00

Molecular and hereditary tumor board
Fortunato Ciardiello, MD; Heinz-Josef Lenz, MD; and Zsofia K. Stadler, MD

Session XIX: Colorectal Cancer

Chairs: Josep Tabernero, MD, PhD and Eric Van Cutsem, MD, PhD

09:30

Presentation of selected abstract

Central evaluation for surgical treatment options in FIRE-3- updated results and impact on overall survival
Dominik Modest et al., O-029

Controversy debate: Updates on treatment algorithms in metastatic CRC in 2017

The ESMO guidelines on metastatic CRC
Eric Van Cutsem, MD, PhD

NCCN guidelines
Alan P. Venook, MD

Asian guidelines
Takayuki Yoshino, MD

The left versus right colon cancer story: What is the truth
Axel Grothey, MD

10:40

Break

11:10

Presentation of selected abstract

FOLFOX4/XELOX in stage II-III colon cancer: Early survival data of the Italian Three Or Six Colon Adjuvant (TOSCA) trial
Roberto Labianca, et al., O-025

11:20

Prospective pooled analysis of six phase III trials investigating duration of adjuvant oxaliplatin-based therapy (3 vs. 6 months) for patients with stage III colon cancer: The IDEA (International duration evaluation of adjuvant chemotherapy)
Thierry André, MD

Discussant: Alan Venook, MD

11:50

Can we refine the selection for adjuvant treatment in colon cancer?
Aimery De Gramont, MD

12:10

Presentation of selected abstract

Randomized phase III study of fluoropyrimidine (FP) plus bevacizumab (BEV) vs. FP plus irinotecan (IRI) and BEV as first-line therapy for metastatic colorectal cancer (mCRC): German AIO KRK0110 (ML22011)- study
Dominik Modest, et al., O-026

Discussant: David Cunningham, MD

12:30

Presentation of selected abstracts

Overall survival analysis of the FOXFIRE, SIRFLOX and FOXFIRE-Global prospective randomized studies of first-line selective internal radiotherapy (SIRT) in patients with liver metastases from colorectal cancer
Harpreet Wasan, et al., O-027

Impact of primary tumour location on survival in patients with metastatic colorectal cancer receiving selective internal radiation therapy and chemotherapy as first-line therapy
Guy van Hazel, et al., LBA-006

Discussant: John Zalcberg, MD

12:55

Session adjourns

13:15

Concurrent luncheon symposia begin

14:45

Concurrent luncheon symposia adjourn

Session XX: Future of GI Oncology

Chairs: Mario Dicato, MD and Alberto Sobrero, MD

14:55

The surgeon of the future
Rodrigo Perez, MD

15:05

The GI endoscopist in the future
Jaroslaw Regula, MD PhD

15:15

The GI oncologist of the future
Axel Grothey, MD

15:25

The radiation oncologist of the future
Vincenzo Valentini, MD, PhD

15:35

The pathologist of the future
Paolo G. Nuciforo, MD

15:45

The radiologist in the future
Raquel Perez Lopez, MD, PhD

15:55

The nuclearist in the future
Christophe Deroose, MD, PhD

Session XXI: Report on Expert Discussion

16:15

Presentation of outcome of expert discussion: Neo-adjuvant/adjuvant treatment
Eric Van Cutsem, MD, PhD, Josep Tabernero, MD, PhD, Mario Dicato, MD

16:30

Congress adjourns